Quick Facts

• Primary Therapeutic Domain: Relief of respiratory congestion.
• Main Use: Used to facilitate the clearing of excess, thick, or sticky mucus from the airways.
• Associated Conditions: Utilized as an adjunct in respiratory conditions such as bronchitis, emphysema, and cystic fibrosis.
• Other Accepted Use: Administered under medical supervision to manage acetaminophen (paracetamol) overdose.

---

What ACC Treats: Main Uses and Benefits

ACC, which contains the active ingredient acetylcysteine, is a medication primarily indicated for therapeutic support in conditions associated with excessive or thick mucus secretions. The use of this drug may help to address congestion in the lungs and air passages.

It is generally used to facilitate the clearing of mucus, phlegm, and respiratory secretions. This process may assist individuals who are experiencing breathing difficulties related to thickened secretions in conditions such as acute and chronic bronchitis, pneumonia, emphysema, and cystic fibrosis.

The mechanism involves reducing the viscosity of the secretions, allowing for easier removal by coughing. This approach to symptom management contributes to respiratory comfort.

Acetylcysteine has an additional, distinct therapeutic application in the hospital setting. It is administered to prevent or lessen potential liver damage following an overdose of acetaminophen (paracetamol), acting as an antidote.

Eligibility and Contraindications for АЦЦ (Acetylcysteine)

Official regulatory documentation defines specific population rules for the use of Acetylcysteine (АЦЦ), distinguishing between contraindicated, restricted, and eligible patient groups.

Absolute Contraindications

Category	Restriction
Hypersensitivity	Contraindicated in patients with a known allergy to acetylcysteine or any excipients.
Pediatric (Mucolytic)	Not recommended for children under mathbf2 years old (mucolytic use).
Respiratory	Contraindicated in patients with acute asthma (inhalation formulation).

---

Population Restrictions and Cautions

Category	Status (Regulatory Wording)
Pregnancy	Use is permitted only if clearly needed (Category B; human data is insufficient).
Lactation	Not advised due to a lack of information on excretion into breast milk.
Pediatric (Antidote)	Intravenous antidote use is approved for patients weighing mathbf5 kg or greater.
Comorbidities	Caution is required for patients with a history of asthma/bronchospasm or those at risk of gastrointestinal hemorrhage.

---

Populations without these documented contraindications or restrictions are generally eligible for use. Patients on a controlled sodium diet and those requiring fluid restriction (pediatric patients < 40 kg for intravenous use) require special consideration due to formulation constraints.

The officially documented interaction profile for АЦЦ (Acetylcysteine) is defined by specific pharmacodynamic effects and procedural constraints on co-administration, as detailed in governmental regulatory information.

Pharmacodynamic Interactions

Co-administration with Nitroglycerin may lead to potentiation of the vasodilatory effect of the nitrate, which could result in significant hypotension (low blood pressure). A relevant interaction exists with antitussive agents (cough suppressants); suppressing the cough reflex may create a risk of retention and accumulation of bronchial secretions, as the thinned mucus is not effectively cleared. This restriction is specifically noted in regulatory documents as being relevant for patients with a reduced cough reflex.

Exposure and Timing Constraints

To avoid a documented reduction in the bioavailability or potential inactivation of certain co-administered drugs, a two-hour separation rule is required. This mandatory time separation applies to both oral antibiotics (including tetracyclines and penicillins) and heavy metal salts (such as gold, iron, and potassium salts) when taken with Acetylcysteine. Conversely, when Acetylcysteine is used in antidote protocols, its effect can be reduced by Activated Charcoal, as the charcoal adsorption significantly lowers the drug's absorption. Official information also notes that concurrent use may result in subtherapeutic plasma levels of Carbamazepine.

The Pharmacodynamics of Acetylcysteine

Acetylcysteine exerts its influence through two distinct biochemical mechanisms: direct mucolysis and indirect antioxidant support. The primary action involves the molecule's free sulfhydryl group ( -SH) engaging in a thiol-disulfide interchange reaction. This process acts as a chemical reductant to cleave the strong disulfide bonds ( S-S) that cross-link the large, high-molecular-weight mucin polymers in respiratory secretions. This bond cleavage results in the depolymerization of the mucus structure, fundamentally reducing its viscosity and elasticity, which facilitates improved fluid dynamics for secretion movement.

Concurrently, Acetylcysteine functions as a prodrug by providing cysteine, the rate-limiting substrate required for the intracellular synthesis of Glutathione ( GSH). This mechanism effectively replenishes the cellular GSH pool, increasing the cell’s capacity to neutralize Reactive Oxygen Species (ROS) and other oxidative molecules. This modulation of oxidative stress contributes to the maintenance of cellular redox homeostasis within the respiratory epithelium.

How Acetylcysteine (АЦЦ) is Used: Administration Guidelines

Acetylcysteine is administered via distinct protocols depending on its therapeutic purpose—mucolytic or antidotal.

---

Administration Routes and Forms

Route	Typical Use Context
Oral	Most common route for mucolytic use (effervescent tablets/granules). Used for antidotal treatment in some protocols.
Intravenous (IV)	Exclusively for the antidotal treatment of acetaminophen overdose in a hospital setting.
Inhalation	Administered via nebulization for targeted mucolytic action in the respiratory tract.

---

Standard Dosing and Preparation

For mucolytic use, the standard oral regimen for adults and adolescents (ge 12 years) is typically 200 mg per dose, taken up to three times daily, not exceeding a maximum of 600 mg per day. The oral forms, such as effervescent tablets or granules, must be fully dissolved in a small amount of water immediately before intake, and fluid intake is often noted to support the desired effect.

The antidotal protocol for acetaminophen overdose requires a precise, sequential, weight-based administration. The intravenous regimen typically involves a total dose of 300 mg/kg delivered in three phases over a total of 21 hours. The concentrated IV solution must be diluted in an appropriate intravenous fluid prior to the timed infusion.

Population and Procedural Rules

Prescribing information specifies that mucolytic products containing acetylcysteine are generally not recommended in children under two years of age. For antidotal use, the dose is calculated based on the patient's body weight in kilograms. Regardless of the route, the solution should not be mixed with other medications in the same container.

Research evidence / Overview of studies for АЦЦ

Evidence for Use in Chronic Respiratory Conditions (COPD and Bronchitis)

Acetylcysteine was evaluated in research exploring its use in conditions like Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis. The primary study designs were Randomized Controlled Trials (RCTs) and meta-analyses that examined outcomes reflecting daily functioning and capturing phases of heightened symptom activity, such as the frequency of acute exacerbations, as well as changes in lung function measurements. Studies report how symptoms evolved in the observed populations, and research indicates an association with certain measured changes. However, findings related to lung function were mixed and varied across different trials. Evidence for long-term changes in lung function remains limited.

Evidence for Use in Acute Toxicological Management

Acetylcysteine was evaluated in a distinct, acute medical scenario: as an antidote for acetaminophen (paracetamol) overdose. Research describes highly standardized protocols and is supported by authoritative consensus. The primary research focus was studied for examining patterns related to the risk of hepatic injury (liver damage), which was monitored using liver enzyme biomarkers. Findings indicate that the compound was associated with patterns related to minimizing the risk of liver damage when administered rapidly. This specific application is widely researched and included in established protocols globally.

Evidence for Other Mucolytic Applications

Studies explored acetylcysteine's use in Cystic Fibrosis and Bronchiectasis, utilizing RCTs to measure changes in lung function and the frequency of pulmonary exacerbations. Findings indicate patterns related to secretion clearance, but evidence quality varies across studies. Data for certain groups, particularly non-CF Bronchiectasis, remain insufficient.

Long-Term Studies and Key Areas of Uncertainty

For chronic conditions like COPD, available evidence is based on trials that have observed responses over defined time intervals, with follow-up durations extending up to three years in some cases. Research explored patterns associated with sustained use on episodic changes. However, comparative evidence is lacking or inconsistent regarding long-term patterns in lung function. Sample sizes were modest in many trials, and findings were mixed when studies explored short-term symptom changes across different global populations. Evidence remains limited for certain specific subgroups and conditions characterized by comorbidities.

Key Studies & References

1. Updated guidelines for the management of paracetamol poisoning in Australia and New Zealand

Common questions about АЦЦ (FAQ)

Q: What are the common side effects of АЦЦ (Acetylcysteine)?

Official regulatory documents classify side effects based on how often they occur. While reactions like nausea, vomiting, abdominal pain, and rash are often listed as 'Uncommon' (affecting less than 1 in 100 people), some sources indicate that symptoms like flushing, low blood pressure (hypotension), or respiratory issues are classified as 'Common' for certain administration routes. In the antidote setting, vomiting can be reported as a very common occurrence.

---

Q: What should I avoid taking with Acetylcysteine (АЦЦ)?

Official information advises special caution and monitoring for concurrent use with Nitroglycerin due to the risk of significantly low blood pressure. Regulatory documents also note a restriction with cough suppressants (antitussives) because suppressing the cough reflex may cause the thinned mucus to accumulate. Furthermore, a time separation is generally required between taking Acetylcysteine and oral antibiotics and certain heavy metal salts (such as iron or gold) to prevent reduced effectiveness.

---

Q: Is it okay to take Acetylcysteine (АЦЦ) while pregnant or breastfeeding?

Official information states that for pregnancy, use is permitted only if clearly needed, as controlled human data on its effects are currently lacking. For breastfeeding, use is generally not advised due to a lack of information regarding whether the drug passes into breast milk and its potential effect on the infant. Some guidelines suggest a period of waiting after use to minimize infant exposure.

---

Q: What should I do if I miss a dose of my АЦЦ (Acetylcysteine)?

If a dose is missed for the mucolytic use, regulatory information generally states to take it as soon as remembered, unless it is almost time for the next scheduled dose. If so, the missed dose is skipped, and the regular schedule continues. The information notes not to take a double dose to compensate. For antidote use, any missed dose must be immediately reported to a healthcare professional.

---

Q: How long does it take for Acetylcysteine (АЦЦ) to start working?

The exact time it takes for the mucolytic (mucus-thinning) effect to begin is not specifically defined in patient information. However, pharmacokinetic studies, which track the drug's path in the body, indicate that the maximum concentration of the drug in the blood is typically reached about two hours after taking the oral effervescent tablet.

Storage and Disposal Instructions for АЦЦ (Acetylcysteine)

Official regulatory documents define specific conditions for storing and disposing of АЦЦ to ensure its stability. The medicine must be stored at or below 25°C (77°F), and it is mandatory to protect it from light and moisture.

Storage Requirement	Instruction
Container	Store in the original container and keep it tightly closed.
Safety	The product must be kept out of the sight and reach of children.

For disposal, do not discard АЦЦ via household waste or wastewater. Unused or expired medication should be returned to a pharmacy or disposed of according to local waste disposal company instructions. Specific formulations, such as the injection, must be handled according to procedures for cytotoxic drugs.